Infrastructure-as-code management platform Spacelift nabs $15M
16 Oct, 2021
– Evox Therapeutics from Oxford closed $95.4m Series C funding.
– The round was led by Redmile Group with participation from new investors OrbiMed and Invus and existing investors Oxford Sciences Innovation (OSI), GV (formerly Google Ventures) and Cowen Healthcare Investments.
– The company intends to use the funds to advance its exosome-based therapeutics pipeline, including progression of several rare disease assets into the clinic, and continued development of its DeliverEXTM exosome drug platform.